Manuscript citation: Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, Verena Dederer, Andreas Krämer, Martin P Schwalm, Nicholas M Lattal, Lewis Elson, Deep Chatterjee, Sebastian Mathea, Thomas Hanke, Andres E Leschziner, Samara L Reck-Peterson, Stefan Knapp (2025) Type II kinase inhibitors that target Parkinson’s disease–associated LRRK2.Science Advances doi: 10.1126/sciadv.adt2050 License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Protocol status: WorkingWe use this protocol and it's working
Created: October 15, 2024
Last Modified: March 13, 2025
Protocol Integer ID: 109897
Keywords: clk3, ligand
Funders Acknowledgements:Aligning Science Across Parkinson’s
Grant ID: 000519